Synaffix to Launch New ADC Technologies at the World ADC Conference in San Diego

Synaffix to Launch New ADC Technologies at the World ADC Conference in San Diego

1. GlycoConnect™ High DAR technology extension enables ADCs with increased loading, while retaining drug substance homogeneity
2. SYN-PNU™ represents a potency-attenuated version of PNU-159,682, the latest addition to the toxSYN™ linker-payload portfolio

AMSTERDAM, THE NETHERLANDS, 12 October 2023 — Synaffix B.V., a Lonza company (SIX:LONN), focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its Founder and head of R&D, prof. Floris van Delft, will present data on the launch of two new technologies during a plenary session at the World ADC conference in San Diego, at 8.15 am PDT on Wednesday 18 October 2023.

GlycoConnect™ High DAR Technology

GlycoConnect™ enables any antibody to be converted into a stable conjugated ADC in a non-genetic fashion, by modifying the native antibody glycan using Synaffix’s efficient enzymes and metal-free click chemistry approach. The extension of GlycoConnect™ with High DAR Technology enables ADCs with high drug loading (6, 8 and above), while retaining high drug substance homogeneity and therapeutic index. 

SYN-PNU™ Linker-Payload

Synaffix’s proprietary toxSYN™ linker-payloads provide multiple options to maximize efficacy by matching the best mechanism of action with the tumor biology specific to the ADC target.  The newest proprietary linker-payload, “SYN-PNU™” is part of the established and expanding toxSYN™ linker-payload portfolio.  SYN-PNU™ represents (based on pre-clinical models) a significantly potency-attenuated and better tolerated version of PNU-159,682, to enable enhanced administered dose levels and competitive therapeutic properties versus ADCs prepared using the original molecule. The reference compound (PNU-159,682) is metabolite of the anthracycline Nemorubicin and represents a highly potent DNA topoisomerase II inhibitor.

Prof. Floris van Delft, Founder and Chief Scientific Officer, Synaffix, said: “I look forward to presenting the underlying data supporting our new High DAR and SYN-PNU™ technologies at the World ADC conference, announcing the addition of a new and powerful Mode-of-Action (MoA) to our tox-SYN™ linker-payload toolbox and demonstrating how we can achieve higher drug loading on any antibody without departing from our ‘engineering free’ approach that all our clients love. We are excited by the potential of these new technologies to further enhance the ability of our licensees to discover, develop and commercialize ADCs with best-in-class therapeutic properties.”